Patents Assigned to Baylor
  • Patent number: 6551996
    Abstract: Inadequate growth due to deficiencies in growth hormone (GR), growth hormone releasing hormone (GHRH), or genetic diseases can be ameliorated utilizing recombinant protein therapy with a novel GHRH analog having a sequence (SEQ ID NO:1). Also included is (1) a method of treating growth hormone-related deficiencies associated with the growth hormone pathway; (2) a method for treating growth hormone-related deficiencies associated with genetic disease; (3) a method to improve growth performance in an animal; (4) a method of treating an animal having a growth deficiency disease; (5) a method of increasing the efficiency of an animal used for food; and, (6) a method to enhance growth in an animal.
    Type: Grant
    Filed: July 24, 2000
    Date of Patent: April 22, 2003
    Assignee: Baylor College of Medicine
    Inventors: Robert J. Schwartz, Ruxandra Draghia-Alki
  • Publication number: 20030068631
    Abstract: The invention concerns making and evaluating synthetic regulatory regions for controlling gene expression. The invention features a method for identifying transcription factor binding sites and a method for evaluating the regulatory functions of synthetic regulatory regions.
    Type: Application
    Filed: May 1, 2002
    Publication date: April 10, 2003
    Applicant: Baylor College of Medicine
    Inventors: Robert J. Schwartz, Eric M. Eastman, Xuyang Li, Jeff Nordstrom
  • Patent number: 6545139
    Abstract: The invention relates to methods for the isolation of metastatic sequences and the isolated sequences. Cells from a cell line or an animal tissue are treated to form a cell line predisposed to cancer. Treated cells are implanted in an animal and incubated for a period of time sufficient for the cells to proliferate and develop malignant transplants. RNA from the malignant transplant and the primary tumor are analyzed by differential display polymerase chain reaction. Differentially expressed genes are cloned, reanalyzed, and sequenced. These genes and sequences can be used as probes in the diagnosis of neoplastic disorders, as probes to isolate metastatic sequences and as a therapeutic agent in the treatment of neoplastic disorders. The metastatic sequence may be a dominant metastatic sequence or a recessive metastatic sequence.
    Type: Grant
    Filed: March 12, 1999
    Date of Patent: April 8, 2003
    Assignee: Baylor College of Medicine
    Inventors: Timothy C. Thompson, Chengzhen Ren
  • Publication number: 20030065271
    Abstract: A device for measuring parameters of human tissue includes a multielectrode catheter for taking multiple measurements of the electrical characteristics of the human tissue, a concentric tube catheter located inside the multielectrode catheter, for providing structural support to the multi-electrode catheter and for serving as a conduit for advancing or withdrawing the multielectrode catheter over its surface; and an imaging catheter located inside the concentric tube catheter for taking multiple measurements of anatomical characteristics of the human tissue.
    Type: Application
    Filed: September 26, 2002
    Publication date: April 3, 2003
    Applicant: Baylor College of Medicine
    Inventor: Dirar S. Khoury
  • Patent number: 6541608
    Abstract: In one embodiment, the present invention is directed to a first oligonucleotide comprising the sequence of or derived from 5′-CTAGGGCGGGCGGGACTCACCTAC-3′ or the nucleic acid sequence complementary thereto. The first oligonucleotide can be used with a nucleic acid of between 15 and 30 nucleotides that does not comprise the sequence of the first oligonucleotide and is found in the region from V&bgr; to J&bgr; of the V&bgr;13.1 gene in V&bgr;13.1 T cells, wherein the sequences of the oligonucleotide and the nucleic acid are not found on the same strand of the V&bgr;13.1 gene pair, to amplify a portion of the V&bgr;13.1 gene. Alternatively, the first oligonucleotide can be used with a labeling moiety in methods of detecting a LGRAGLTY motif found in T cell receptors of V&bgr;13.1 T cells. This motif is associated with autoimmune diseases, such as multiple sclerosis (MS). Once the motif is detected, the autoimmune disease can be treated or its progress monitored.
    Type: Grant
    Filed: August 18, 2000
    Date of Patent: April 1, 2003
    Assignee: Baylor College of Medicine
    Inventor: Jingwu Z. Zhang
  • Publication number: 20030055017
    Abstract: Vectors which establish controlled expression of recombinant GHRH genes within tissues at certain levels. The vector includes a 5′ flanking region which includes necessary sequences for expression of a nucleic acid cassette, a 3′ flanking region including a 3′ UTR and/or 3′ NCR, and a linker which connects the 5′ flanking region to a nucleic acid sequence. The linker has a position for inserting a nucleic acid cassette. The linker does not contain the coding sequence of a gene that the linker is naturally associated with. The 3′ flanking region is 3′ to the position for inserting the nucleic acid cassette.
    Type: Application
    Filed: April 16, 2002
    Publication date: March 20, 2003
    Applicant: Baylor College of Medicine and GeneMedicine
    Inventors: Robert J. Schwartz, Ruxandra Draghia-Akli, Xuyang Li, Eric M. Eastman
  • Patent number: 6534067
    Abstract: This invention relates to a method of potentiating an immune response by administering a viral enterotoxin or derivative as an adjuvant. More particularly it relates to administering a viral enterotoxin or derivative as an adjuvant and an antigen to a mucosal surface of a mammal.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: March 18, 2003
    Assignee: Baylor College of Medicine
    Inventor: Mary K. Estes
  • Patent number: 6528320
    Abstract: The present invention comprises a sample presentation apparatus for mass spectrometry. More particulary, a complex is immoblized on the sample presenting surface.
    Type: Grant
    Filed: December 20, 2000
    Date of Patent: March 4, 2003
    Assignee: Baylor College of Medicine
    Inventors: T. William Hutchens, Tai-Tung Yip
  • Publication number: 20030003496
    Abstract: The invention provides compositions and methods for generating a molecular profile of genomic DNA by hybridization of labeled nucleic acid representing the genomic DNA to immobilized nucleic acid probes, e.g., arrays or biochips.
    Type: Application
    Filed: July 26, 2002
    Publication date: January 2, 2003
    Applicant: Baylor College Medicine, a Texas corporation
    Inventors: Allan Bradley, Wei-Wen Cai
  • Publication number: 20020187505
    Abstract: Assays for analyzing or genotyping a test sample comprising nucleic acid are described, wherein the assays comprise contacting a prepared test sample containing nucleic acid with an array comprising a set of oligonucleotides attached to a solid support at identifiable locations, wherein each oligonucleotide in the set comprises a first boundary sequence at a proximal end of the oligonucleotide, a second boundary sequence at a distal end of the oligonucleotide, a nucleic acid marker between the first and second boundary sequences, and a label at the distal end of the oligonucleotide; maintaining the contacted array under conditions which allow hybridization of nucleic acid in the test sample to the oligonucleotides of the array; subjecting the hybridized array to a cleavage agent, wherein the cleavage agent cleaves incompletely hybridized oligonucleotides but does not cleave completely hybridized oligonucleotides; washing the cleaved array to remove cleavage products from the cleaved array; and assessing a pat
    Type: Application
    Filed: May 16, 2002
    Publication date: December 12, 2002
    Applicant: Baylor College of Medicine
    Inventor: David W. Stockton
  • Publication number: 20020182698
    Abstract: The present invention provides mutant proteins of steroid hormone receptors. These mutant proteins are useful in methods of distinguishing a steroid hormone receptor antagonist from a steroid hormone receptor agonist. The present invention also provides plasmids containing mutated steroid hormone receptor proteins and cells transfected with those plasmids. In addition, the present invention provides methods for determining whether a compound is a steroid hormone receptor antagonist or agonist. Also, the present invention provides methods of determining endogenous ligands for steroid hormone receptors. The invention further provides a molecular switch protein for regulating expression in gene therapy.
    Type: Application
    Filed: April 16, 2002
    Publication date: December 5, 2002
    Applicant: Baylor College of Medicine
    Inventors: Bert W. O'Malley, Ming-Jer Tsai, Sophia Y. Tsai, Harry C. Ledebur, Yaolin Wang, Joseph D. Kittle
  • Publication number: 20020173456
    Abstract: Peptide-macromolecule complexes for delivery of nucleic acid to a cell. The nucleic acid carrier includes a binding complex. The binding complex contains a binding moiety which noncovalently binds to the nucleic acid. The binding complex can also contain a binding moiety which is associated with a surface ligand, nuclear ligand or a lysis agent. These may be associated with the binding moiety by spacers. In addition, the carrier may include a nucleic acid with a combination of the above binding complexes or binding moieties.
    Type: Application
    Filed: March 12, 2001
    Publication date: November 21, 2002
    Applicant: Baylor College of Medicine
    Inventors: Louis C. Smith, James T. Soarrow, Jochen Hauer, Martha P. Mims
  • Patent number: 6479263
    Abstract: Prostate cancer is detected by determining the presence of hK2 RNA in a physiological sample.
    Type: Grant
    Filed: April 11, 1997
    Date of Patent: November 12, 2002
    Assignees: Baylor College of Medicine, Mayo Foundation for Medical Education and Research
    Inventors: Kevin M. Slawin, Donald J. Tindall, Charles Y. F. Young, Mohammad Saeed Saedi, Abhay Kumar, Harry G. Rittenhouse, Robert L. Wolfert
  • Patent number: 6475434
    Abstract: A biofilm penetrating composition for coating medical devices for substantially preventing the growth or proliferation of biofilm embedded microorganisms on at least one surface of the medical device is disclosed. A biofilm penetrating composition solution for cleaning medical devices which is capable of substantially removing all of the biofilm embedded microorganisms from at least one surface of medical devices is also disclosed. The biofilm penetrating composition coating and solution include a biofilm penetrating agent and may also include a base material. Medical devices coated with the biofilm penetrating composition and methods for coating medical devices and methods for removing biofilm embedded microorganisms from at least one surface of the medical devices are also disclosed.
    Type: Grant
    Filed: December 6, 1999
    Date of Patent: November 5, 2002
    Assignee: Baylor College of Medicine
    Inventor: Rabih O. Darouiche
  • Patent number: 6475745
    Abstract: The present invention is directed to screening for an agent that inhibits the effect of a neurotoxin from a plaque component activated mononuclear phagocyte on a neuron. In addition, the present invention is directed to methods of screening for agents that inhibit mononuclear phagocyte-plaque component complex formation, plaque component activation of a mononuclear phagocyte, plaque component induced neurotoxicity of a mononuclear phagocyte. An agent obtained by the method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation and a pharmaceutical composition comprising the agent are embodied by the present invention.
    Type: Grant
    Filed: September 3, 1997
    Date of Patent: November 5, 2002
    Assignee: Baylor College of Medicine
    Inventor: Dana Giulian
  • Patent number: 6475742
    Abstract: The present invention is directed to screening for an agent that inhibits the effect of a neurotoxin from a plaque component activated mononuclear phagocyte on a neuron. In addition, the present invention is directed to methods of screening for agents that inhibit mononuclear phagocyte-plaque component complex formation, plaque component activation of a mononuclear phagocyte, plaque component induced neurotoxicity of a mononuclear phagocyte. An agent obtained by the method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation and a pharmaceutical composition comprising the agent are embodied by the present invention.
    Type: Grant
    Filed: September 3, 1997
    Date of Patent: November 5, 2002
    Assignee: Baylor College of Medicine
    Inventor: Dana Giulian
  • Patent number: 6461818
    Abstract: The present invention involves the creation of defined chromosomal deficiencies, inversions and duplications using Cre recombinase in ES cells transmitted into the mouse germ line. These chromosomal reconstructions can extend up to 3-4 cM. Chromosomal rearrangements are the major cause of inherited human disease and fetal loss. Additionally, translocations and deletions are recognized as major genetic changes that are causally involved in neoplasia. Chromosomal variants such as deletions and inversions are exploited commonly as genetic tools in organisms such as Drosophila. Mice with defined regions of segmental haploidy are useful for genetic screening and allow accurate models of human chromosomal diseases to be generated.
    Type: Grant
    Filed: April 19, 2000
    Date of Patent: October 8, 2002
    Assignee: Baylor College of Medicine
    Inventors: Allan Bradley, Ramiro Ramirez-Solis, Pentao Liu, Hong Su, Binhai Zheng
  • Publication number: 20020142355
    Abstract: The present invention is directed to methods that can used for biotin labeling polypeptides in mammalian cells. The methods can be effectively used for cytoplasmic proteins, secreted proteins, and for proteins found on viral surfaces.
    Type: Application
    Filed: November 14, 2001
    Publication date: October 3, 2002
    Applicant: Baylor College of Medicine
    Inventors: Michael A. Barry, Michael B. Parrott
  • Patent number: 6451544
    Abstract: The present invention is directed to screening for an agent that inhibits the effect of a neurotoxin from a plaque component activated mononuclear phagocyte on a neuron. In addition, the present invention is directed to methods of screening for agents that inhibit mononuclear phagocyte-plaque component complex formation, plaque component activation of a mononuclear phagocyte, plaque component induced neurotoxicity of a mononuclear phagocyte. An agent obtained by the method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation and a pharmaceutical composition comprising the agent are embodied by the present invention.
    Type: Grant
    Filed: September 3, 1997
    Date of Patent: September 17, 2002
    Assignee: Baylor College of Medicine
    Inventor: Dana Giulian
  • Publication number: 20020102646
    Abstract: The present invention provides transcription factors associated with the hedgehog signaling pathway that are regulated by dephosphorylation by phosphatases. Hedgehog response elements (HRE) that interact with the dephosphorylated transcription factors are also provided as well as methods for identifying compounds that are phosphatase inhibitors. Methods of treating tumors in a subject by modulating the phosphorylation of the transcription factor are also included.
    Type: Application
    Filed: August 21, 2001
    Publication date: August 1, 2002
    Applicant: Baylor College of Medicine
    Inventors: Philip A. Beachy, Ming-Jer Tsai, Sophia Tsai, Venkatesh Krishnan, Chien-Huan Chen